tetano
Editor, Senior Moderator
Vaccine. 2019 Oct 4. pii: S0264-410X(19)31324-6. doi: 10.1016/j.vaccine.2019.09.082. [Epub ahead of print] [h=1]Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Instituto Butantan.[/h]
Koike ME[SUP]1[/SUP], Gatt?s VL[SUP]2[/SUP], Lucchesi MBB[SUP]2[/SUP], Moura de Oliveira MM[SUP]2[/SUP], Vanni T[SUP]2[/SUP], Thom? BDC[SUP]2[/SUP], Menang O[SUP]3[/SUP], Socquet M[SUP]3[/SUP], Precioso AR[SUP]4[/SUP].
[h=3]Author information[/h] 1 Division of Clinical Trials and Pharmacovigilance, Instituto Butantan, S?o Paulo, Brazil. Electronic address: marcelo.koike@butantan.gov.br. 2 Division of Clinical Trials and Pharmacovigilance, Instituto Butantan, S?o Paulo, Brazil. 3 Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland. 4 Division of Clinical Trials and Pharmacovigilance, Instituto Butantan, S?o Paulo, Brazil; Pediatrics Department of the School of Medicine of University of S?o Paulo, S?o Paulo, Brazil.
[h=3]Abstract[/h] Instituto Butantan is a biomedical research center and vaccine manufacturer affiliated with the S?o Paulo State Secretary of Health in Brazil. In 2013, Instituto Butantan successfully licensed its trivalent influenza vaccine, in order to support the Brazilian National Immunization Program's influenza vaccination strategy, which was introduced in 1999. In order to respond to the increasing influenza vaccine demand worldwide, Instituto Butantan is undergoing prequalification of its trivalent influenza vaccine by the World Health Organization (WHO). A key requirement of the prequalification review was the submission of a pharmacovigilance plan, including an active surveillance evaluation, for the trivalent influenza vaccine, and proof of a functional pharmacovigilance system at Instituto Butantan. The aim of this paper is to describe the capacity strengthening process of the pharmacovigilance system at Instituto Butantan for the WHO prequalification of the trivalent influenza vaccine. This process was supported by PATH and the U.S. Federal Government Biomedical Advanced Research and Development Authority (BARDA). The key strategic axes for this capacity strengthening process included the improvement of organizational structure, human resources training, internal processes and procedures, appropriate documentation, and acquisition of an E2B compliant pharmacovigilance database. The project led to the establishment of a functional pharmacovigilance system compliant with international regulatory requirements.
Copyright ? 2019 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Instituto Butantan; Pharmacovigilance; Trivalent influenza vaccine; WHO prequalification
PMID: 31590933 DOI: 10.1016/j.vaccine.2019.09.082
Koike ME[SUP]1[/SUP], Gatt?s VL[SUP]2[/SUP], Lucchesi MBB[SUP]2[/SUP], Moura de Oliveira MM[SUP]2[/SUP], Vanni T[SUP]2[/SUP], Thom? BDC[SUP]2[/SUP], Menang O[SUP]3[/SUP], Socquet M[SUP]3[/SUP], Precioso AR[SUP]4[/SUP].
[h=3]Author information[/h] 1 Division of Clinical Trials and Pharmacovigilance, Instituto Butantan, S?o Paulo, Brazil. Electronic address: marcelo.koike@butantan.gov.br. 2 Division of Clinical Trials and Pharmacovigilance, Instituto Butantan, S?o Paulo, Brazil. 3 Center for Vaccine Innovation and Access, PATH, Geneva, Switzerland. 4 Division of Clinical Trials and Pharmacovigilance, Instituto Butantan, S?o Paulo, Brazil; Pediatrics Department of the School of Medicine of University of S?o Paulo, S?o Paulo, Brazil.
[h=3]Abstract[/h] Instituto Butantan is a biomedical research center and vaccine manufacturer affiliated with the S?o Paulo State Secretary of Health in Brazil. In 2013, Instituto Butantan successfully licensed its trivalent influenza vaccine, in order to support the Brazilian National Immunization Program's influenza vaccination strategy, which was introduced in 1999. In order to respond to the increasing influenza vaccine demand worldwide, Instituto Butantan is undergoing prequalification of its trivalent influenza vaccine by the World Health Organization (WHO). A key requirement of the prequalification review was the submission of a pharmacovigilance plan, including an active surveillance evaluation, for the trivalent influenza vaccine, and proof of a functional pharmacovigilance system at Instituto Butantan. The aim of this paper is to describe the capacity strengthening process of the pharmacovigilance system at Instituto Butantan for the WHO prequalification of the trivalent influenza vaccine. This process was supported by PATH and the U.S. Federal Government Biomedical Advanced Research and Development Authority (BARDA). The key strategic axes for this capacity strengthening process included the improvement of organizational structure, human resources training, internal processes and procedures, appropriate documentation, and acquisition of an E2B compliant pharmacovigilance database. The project led to the establishment of a functional pharmacovigilance system compliant with international regulatory requirements.
Copyright ? 2019 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Instituto Butantan; Pharmacovigilance; Trivalent influenza vaccine; WHO prequalification
PMID: 31590933 DOI: 10.1016/j.vaccine.2019.09.082